Quantum Molecular Resonance Effects On Patients With Dry Eye Disease: A Randomised-Controlled Trail

To evaluate efficacy and safety of Quantum Molecular Resonance in the treatment of dry eye disease.

Ophthalmology department in one academic medical center, February 2021 to February 2022.

A randomised control trial was conducted. Participants randomized into two groups: treatment and placebo. Patients in the treatment group received 4 treatments,  once a week for 4 weeks. Patients in the placebo group received 4 sham treatments (with no power). Ocular Surface Disease Index (OSDI), corneal fluorescein staining, tear break-up time (TBUT), Schirmer's test and meibomian gland dysfunction (MGD) score before and following treatment.

Thirty-two patients were recruited, 16 in each arm. The mean age was 63.5±13.7 years and 21 (65.6%) were female. The mean OSDI score significantly improved in the treatment group from 17.4±9.0 to 9.43±6.8 (p<0.001) while the placebo group showed no significant change (14.0±9.2 to 12.31±7.4, p=0.465). MGD scores significantly improved in the treatment group (1.56±1.1 to 1.0±0.9, p=0.040) while showing no significant change in the placebo group (1.65±1.1 to 2.0±1.1, p=0.337). Corneal staining and Schirmer scores showed no significant change in either group (1.9±2.0 to 1.2±1.5, p=0.216 and 8.1±7.4 to 8.5±4.9mm, p=0.750 in the treatment group and 2.2±2.2 to 2.7±2.1, p=0.325 and 11.7±8.3 to 13.6±6.6 mm, p=0.316 in the placebo group).

High frequency electrotherapy has a positive effect on symptoms and signs of patients with dry eyes. This emerging technology may be added to the arsenal of therapeutic agents for this condition. Further studies will need to confirm these results.